期刊文献+

骨桥蛋白和血管内皮生长因子-C蛋白在浸润性乳腺癌组织中的表达及意义 被引量:6

下载PDF
导出
摘要 目的检测乳腺良、恶性病变及正常乳腺组织中骨桥蛋白(OPN)和血管内皮生长因子-C(VEGF-C)蛋白的表达情况,并分析与相关临床病理学参数的关系,为进一步完善浸润性乳腺癌的发生、发展机制及预后判断提供有价值的生物学指标。方法采用免疫组织化学SP法检测120例乳腺癌组织及80例乳腺良性病变组织和40例正常乳腺组织中OPN与VEGF-C蛋白的表达情况。结果 OPN、VEGF-C蛋白在正常乳腺组织、良性乳腺病变组织及浸润性乳腺癌组织中的阳性表达率分别为2.5%、20.0%、69.1%和7.5%、23.8%、65.0%,组间比较差异有统计学意义(P<0.05);同时两者的表达与肿瘤大小及腋窝淋巴结转移情况密切相关(P<0.05),但与组织学类型及雌激素、孕激素受体表达情况无显著相关性(P>0.05)。蛋白之间的相关性分析显示,两者之间呈明显的正相关关系(r=12.813,P<0.05)。结论 OPN与VEGF-C蛋白的表达与浸润性乳腺癌的进展有一定的相关性,联合检测两者的表达可以对浸润性乳腺癌的治疗及预后判断助提供一定的理论依据。
作者 王征 王永霞
出处 《广东医学》 CAS CSCD 北大核心 2013年第12期1901-1903,共3页 Guangdong Medical Journal
  • 相关文献

参考文献12

  • 1ROSS L, CAAN B, ROWAN T, et al. Low - fat dietary pattern and rick of invasive breast cancer [ J ]. JAMA, 2006, 295 ( 6 ) : 629 - 642.
  • 2LIN F, LI Y, CAO J, et al. Overexpression of osteopontin in hepa- tocellular carcinoma and its relationships with metastasis, invasion of tumorcells[J]. MolBiolRep, 2011, 38(8): 5205-5210.
  • 3MI Z, BHATTACHARYA S D, KIM V M, et al. Osteopontin pro- motes CCI5 - mesenchymal stromal cell - mediated breast cancer metastasis[ J]. Carcinogenesis, 2011, 32 (4) : 477 -487.
  • 4DAVID G. New molecular markers for the study of tumour Lym- phangio genesis [ J]. Anticancer Res, 2001, 21 (6B) : 4279 - 4283.
  • 5SASAKI M, HUANG S F, CHEN M F, et al. Expression of deleted in malignant brain tumor - 1 ( DMBTI ) molecule in biliary epitheli- um is augmented in hepatolithiasis: Possible participation in litho- genesis[ J]. Dig Dis Sci, 2003, 48(7) : 1234 - 1240.
  • 6EL TANANI M K, CAMPBELL F C, KURISETI'Y V, et al. The regnlation and role of osteopontin in malignant transformation and cancer[ J]. Cytokine Growth Factor Rev, 2006, 17 (6) : 463 - 474.
  • 7LIN Y H, YANG YEN H F. The osteopontin CD44 survial signal involves activation of the phosphatidylinositol 3 - kinase/Akt signa- ling pathway [ J ]. Biol Chem, 2001,276 (49) : 46024 - 46030.
  • 8WANG K X, DENHARDT D T. Osteopontin: role in immune regu- lation and stress responses [ J ]. Cytokine Growth Factor Rev,2008, 19(5/6): 333 -345.
  • 9COPPOLA D, SZABO M, BOULWARE D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies[J]. Clin Cancer Res, 2004, 10( 1 Pt 1) : 184 -190.
  • 10常超(综述),王平(审校).淋巴管生成的分子机制与恶性肿瘤的淋巴转移[J].中国癌症杂志,2009,19(5):391-395. 被引量:11

二级参考文献25

  • 1Wittem H,Jone K,Wltng J,et al.Structure function relationships in the lymphatic system and implications for cancer biology[J].Cancer Metastasis Rev,2006,25(2):159-184.
  • 2Dumont DJ,Jussila L,Taipale J,et al.Cardiovascular failure in mouse embryos deficient in VEGF receptor-3[J].Science,1998,282(5390):946-949.
  • 3Padera TP,Kadambi A,di-Tomaso E,et al.Lymphatic metastasis in the absence of functional intratumor lymphatic[J].Science,2002,296(5574):1883-1886.
  • 4Breiteneder-Geleff S,Soleiman A,Kowalski H,et al.Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries:podoplanin as a specific marker for lymphatic endothelium.Am J Pathol,1999,154(2):385-394.
  • 5Hong YK,Harvey N,Noh YH,et al.Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate[J].Bey Dyn,2002,225(3):351-357.
  • 6Joukov V,Pajusola K,Kaipainen A,et al.A novel vascular endothelial growth factor,VEGF-C,is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases[J].EMBO J,1996,15:290-298.
  • 7Achen MG,Jeltsch M,Kukk E,et al.Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyresine kinases VEGF receptor-2 (Flk-1) and VEGF receptor-3 (Flt-4)[J].PNAS,1998,95:548-553.
  • 8Su JL,Yen C J,Chen PS,Chuang SE,Hong CC,Kuo IH,et al.The role of the VEGF-C/VEGFR-3 axis in cancer progression[J].BrJ Cancer,2007,96:541-545.
  • 9Jeltsch M,Kaipainen A,Joukov V,et al.Hyperplasia of lymphatic vessels in VEGF-C transgenic mice[J].Science,1997,276(5317):1423-1425.
  • 10Hirakawa S,Brown LF,Kodama S,et al.VEGF-C induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites[J].Blood,2007,109:1010-1017.

共引文献10

同被引文献57

  • 1Bockelman C, Koskcnsalo S, Hagstrom J, et al. CIP2A overexpression is associated with c-Myc expression in colorectal cancer[ J ]. Cancer Biol T- her,2012,13 (5) :289 -295.
  • 2Ren'J,Li W,Yan L,et al. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival [ J ]. Br J Cancer,2011,105(12) :1905 - 1911.
  • 3Siegel R, Naishadham 0,Jemal A. Cancer statistics for Hispanicsl Latinos, 2012[J]. CA CancerJ Clin, 2012, 62(1): lO-29.
  • 4Lin F, Li Y, CaoJ, et al. Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion Of tumor cells[J]. Mol Bioi Rep, 2011, 38(8): S20S-S2lO.
  • 5Mi Z, Bhattacharga SO, Kin VM, et al. Osteopontin promotes CCLS-mesenchymal stromal cell-mediated breast cancer metastasis[J]. Carcinogenesis, 2011, 32(4): 477-487.
  • 6KinoshitaJ, Kitamura K, Kabashima A, et al. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer[J]. Breast Cancer Res Treat, 2001, 6(2): 159-164.
  • 7Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer[J]. Breast Cancer Res Treat, 200S, 91(2): 12S-132.
  • 8Guo B, Zhang Y, Lou G, et al. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor Iymphangiogenesis and growth in breast carcinoma[J]. Anat Rec (Hoboken), 2009, 292(S): 633-639.
  • 9Brito LG, Schiavon VF, Andrade 1M, et al. Expression of Hypoxia-inducible factor I-a and Vascular endothelial growth factor-C in locally advanced breast cancer patients[J]. Clinics (Sao Paulo), 2011,66(8): 1313-1320.
  • 10WangJ, Guo Y, Wang B, et al. Lymphatic microvesse1 density and vascular endothelial growth factor-C and -0 as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature[J] . Mol Bioi Rep, 2012, 39(12): 11153-11165.

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部